机译:KRAS突变,持续有机污染物和微量元素对胰腺导管腺癌生存的影响
School of Medicine Universitat Autonoma de Barcelona Barcelona Spain CIBER de Epidemiologia y Salud Publica (CIBERESP) Madrid Spain Hospital Del Mar Medical Research Institute (IMIM) Barcelona Spain;
CIBER de Epidemiologia y Salud Publica (CIBERESP) Madrid Spain Hospital Del Mar Medical Research Institute (IMIM) Barcelona Spain;
National Heart and Lung Institute Imperial College London London United Kingdom;
Department of Epidemiology Columbia University New York USA Herbert Irving Comprehensive Cancer Center Columbia University Medical Center New York USA;
School of Medicine Universitat Autonoma de Barcelona Barcelona Spain Hospital Del Mar Medical Research Institute (IMIM) Barcelona Spain;
Harvard Medical School Harvard T. H. Chan School of Public Health Brigham and Women's Hospital Boston USA;
CIBER de Epidemiologia y Salud Publica (CIBERESP) Madrid Spain Universidad de Huelva Huelva Spain;
School of Medicine Universitat Autonoma de Barcelona Barcelona Spain CIBER de Epidemiologia y Salud Publica (CIBERESP) Madrid Spain Hospital Del Mar Medical Research Institute (IMIM) Barcelona Spain;
Harvard Medical School Harvard T. H. Chan School of Public Health Brigham and Women's Hospital Boston USA;
CIBER de Epidemiologia y Salud Publica (CIBERESP) Madrid Spain IMIB-Arrixaca Department of Public Health Sciences University of Murcia;
School of Medicine Universitat Autonoma de Barcelona Barcelona Spain Hospital Del Mar Medical Research Institute (IMIM) Barcelona Spain;
Harvard Medical School Harvard T. H. Chan School of Public Health Brigham and Women's Hospital Boston USA;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina Chapel Hill USA;
persistent organic pollutants (POPs); trace elements; metals; pancreatic cancer; pancreatic ductal adenocarcinoma (PDAC); survival; KRAS oncogene;
机译:胰腺导管腺癌中微量元素和KRAS KRAS突变的浓度
机译:致癌erbb2像畸变和Kras突变合作,促进胰腺导管腺癌进展
机译:使用切除胰腺导管腺癌桡骨切除缘的超敏性数字聚合酶链反应对克拉斯突变负担复发预测
机译:纹理分析对胰腺癌新辅助化疗患者生存率的预测
机译:胰腺导管腺癌前体的腺泡可塑性和Kras依赖性规格。
机译:KRAS野生型突变状态赋予胰腺导管腺癌生存优势
机译:KRAS和TP53突变与切除的胰腺导管腺癌的较低生存率相关